Catalyst Wire Dossier Catalyst Wire Dossier

MK-4250

· Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-4250, covering 2019-10-30 to 2019-10-30. Get the full timeline:

Most recent: Clinical Trial Update: Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002) [Phase 1]

See pricing